



1. Abstract Proposals<sup>#</sup> and all accompanying materials must be electronically submitted no later than January 22, 2024.
2. We consider the Abstract Presentations to be an educational activity, and therefore must avoid commercialism and be free of bias. All sources of support must be acknowledged on the Poster.
3. Generic names should be used versus brand names when possible. Also, the use of words such as novel, unique, robust, and excellent is thought to be promotional, and must be substantiated by proper references or *P*-values. When possible, use pharmacologic agent, medication, therapy, or a similar term, instead of drug.
4. No encore presentations from other conferences occurring before April 2024 will be accepted unless new data is being presented. All disclaimers regarding publishing or submitting for publication must be disclosed.
5. Abstract Proposals will be reviewed and selected by members of the Abstract Committee. Those selected will be notified at least six weeks prior to the April 4-6, 2024 meeting.
6. All accepted abstracts will be required to provide an electronic poster for display at the annual meeting. All will be responsible for all personal expenses (travel, hotel, etc.). ASIPP will only pay for the conference registration for the TOP 10 presenters. Presenters must be registered and present for the meeting on the days Posters will be on display.
7. A non-refundable \$50 submission fee will be required for submissions, and will be collected with the online abstract submission form.
8. Posters will be on display electronically during the meeting Thursday, April 4 through Saturday, April 6. Presenters are asked to be available during breaks and the final 10 minutes of lunchtime for questions during these three days.
9. The **Top 10** will present during the abstract breakout session. The selected **Top 3** will present during the General Session of the meeting. All accepted abstracts will be published in an issue of *Pain Physician*.
10. ASIPP must have mobile phone numbers for the presenter and primary contact for urgent communication at the venue during the meeting. Mobile numbers will be kept confidential.

<sup>#</sup>Case reports may be submitted for consideration